

### REMARKS

Restriction was required under 35 U.S.C. 121 and 372 between the following three groups of claims:

- Group I: Claims 1-10, 31, and 32, drawn to a process for administering biologically active agent(s) in a form that releases progressively increasing doses.
- Group II: Claims 12-25, drawn to a biologically active agent delivery composition.
- Group III: Claims 26-28, drawn to a multicompartmental capsule.

### Response to Restriction Requirement

Applicant elects Group I, encompassing claims 1-10, 31, and 32 drawn to a process for administering biologically active agent(s) in a form that releases progressively increasing doses.

Claims 12-28 have been canceled solely on the basis that they are directed to a non-elected invention. Claim 32 has been canceled in view of the cancellation of Claim 15 from which it formerly depended.


Claim 1 has been amended to further distinguish the claimed invention over the Hashmi et al. reference cited by the Examiner in the restriction requirement. This reference discloses two progressively increasing doses, but does not disclose delivery of at least three progressively increasing doses of biologically active agent that are administered to an animal on a single occasion, as presently claimed.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 7 January 2008

By:   
Raymond D. Smith  
Registration No. 55,634  
Agent of Record  
Customer No. 20995  
(805) 547-5580